Spring direct naar de hoofdnavigatie of de inhoud

Mark Einerhand

Patent attorney

“In the end it's all about the value that the patent adds to the product.”
Home / Experts / Mark Einerhand

Mark Einerhand

Mark Einerhand

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner

Mark Einerhand has been active in the patent world since 1998, when he made the switch from a biotech startup to V.O.

Mark’s career started in science. After his studies of molecular biology at the University of Amsterdam, he took his PhD in medical science inLeiden, in 1992. He was a visiting scientist at Cornell University in New York and the MRC at Mill Hill in London.

More information about Mark

His particular expertise lies in the field of medical (bio)technology, diagnostics and medicines. Because of his background at Introgene/Crucell, Mark has a special affinity with Life Science startups. He has a wide experience in patent cases before the court in The Hague.

Working experience

  • Patent Attorney, V.O. (1998-present)
  • IntroGene (now Crucell), Rijswijk (1995)
  • Post-Doc at Leiden University (1993)
  • Medical Research Council, Mill Hill, London (1992)
  • Visiting Scientist, Cornell University New York (1992)

Education

  • PhD in Medicine, Leiden University (1992)
  • MSc in Biochemistry, University of Amsterdam (1987), Major in Molecular Oncology, Dutch Cancer Institute

Publications

  • Co-author of article ‘The patentability of stem cells in Europe’, IAM Life Sciences 2015.
    Einerhand, M.P.W. (2011): Advance offering of generics found to infringe. Managing Intellectual Property: Vol 205: page: 87.
  • Einerhand M.P.W. (2010): A contribution to: Legal and intellectual property issues associated with stem cells. In: Stem Cells; scientific facts and fiction, (C. Mummery; I. Wilnut, A van de Stolpe and
    B.A.J. Roelen), Academic Press: Elsevier.
  • Einerhand M.P.W. and van Melle, J (2004): Patenting of inventions in the field of bio-informatics.
    In: The new avenues in Bioinformatics, (Seckbach, J and Rubin, E eds), Kluwer Academic Publishers, the Netherlands.
  • Principle inventor on Patents and Patent Applications: Einerhand, M.P.W. and Valerio (1997). WO 98/32870: US 6,232,105: A conditional replication and expression system. Einerhand, M.P.W. and Valerio (1997). WO 99/32647: Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into chromosomal DNA of target cells in gene therapy. Einerhand, M.P.W. and Valerio (1996). WO98/24924: NZ 336185:
  • Transduction of primate hemopoietic repopulating stem cells. Einerhand, M.P.W. and Valerio (1995). WO 97/20943: US 6,140,103: Regulated protein expression in stably transfected mammalian cells. Einerhand, M.P.W. (1992) Gene transfer into hemopoietic stem cells: prospects for human gene therapy. University of Leiden.

Professional & Community Activities

  • Member of the Steering Committee World IP Forum 2015
    Former member of the European Qualifying Examination committee III

Languages

  • English
  • Dutch
  • German

Also see these experts

Annemiek Tepper

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Marijke Westra

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
More experts

News

The consequences of the Nagoya Protocol

  The Nagoya Protocol is highly relevant for the Dutch seed culture sector. But the content of the protocol is far from easy to understand. IP Leads summarises the main provisions for you and the most important consequences.Continue reading

No happy ending for a pharmaceutical company in a case involving a Native American tribe

In the case known as Mohawk tribe versus Mylan, the US Federal Circuit Court of Appeals ruled that patent holders cannot shield themselves from an “inter partes review” of a patent by assigning that patent to a Native American tribe. Ironically enough, this is due to the fact that the decision handed down by the […]Continue reading

Does the new law for the protection of trade secrets offer sufficient protection?

On 9 June, the new law for the protection of trade secrets came into force (based on European Directive 2016/943/EU). On the basis of the law, it is possible to take action against the illegal acquisition, use and disclosure of trade secrets. If a trade secret is misused, the holder can bring various actions based […]Continue reading

Events

European Biotech and Pharma Partnering Conference 2018

Osaka, Japan,Congres Convention Centre Second Basement, North Building, Grand Front Osaka

The European Biotech and Pharma Partnering Conference in Osaka offers business contacts to industry professionals who are looking for potential partners in the EU and Japan to ensure sustainable business development and growth. More about this event

BIO JAPAN 2018 – Flemish Life Sciences & Biotech Week

Pacifico Yokohama, 1 Chome-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa, Japan

Asia's Premier Partnering Event for the Global Biotechnology Industry BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades. More about this event

The London IP Summit 2018

Four Seasons Hotel London at Park Lane, Hamilton Place, Park Lane, London, Verenigd Koninkrijk

The London IP Summit is an industry leading event dedicated to bringing together IP owners, experts and investors to address key challenges and operational issues faced by companies and IP professionals today. More about this event